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Purpose: To compare the IOP-lowering efﬁ  cacy of the ﬁ  xed combination of travoprost 0.004%/
timolol 0.5% dosed once daily in the morning with the concomitant administration of travoprost 
0.004% dosed once daily in the evening and timolol 0.5% dosed once daily in the morning.
Methods: This was an analysis of pooled data from two similarly designed prospective, ran-
domized, controlled clinical trials comparing the ﬁ  xed combination and concomitant therapy. 
Results: Mean IOP ranged from 15.7 to 16.8 mmHg for the ﬁ  xed combination group, and from 
15.1 to 16.4 mmHg for the concomitant group. Mean IOP reductions were up to 9.0 mmHg in 
the ﬁ  xed combination group, and up to 8.8 mmHg in the concomitant group. The differences 
in mean IOP change between treatment groups ranged from –0.2 to +0.9 mmHg across visits 
and time points. The safety proﬁ  le was generally similar between groups. An exception was 
the incidence of ocular hyperemia, which was 13.7% with the ﬁ  xed combination and 20.8% 
with concomitant therapy (p = 0.02).
Conclusion: The ﬁ  xed combination of travoprost 0.004% and timolol 0.5% provides IOP-
lowering efﬁ  cacy that is similar to concomitant administration of travoprost 0.004% dosed once 
daily in the evening and timolol 0.5% dosed once daily in the morning.
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Introduction
Travoprost is a member of the prostaglandin analogue class of intraocular pressure 
(IOP)-lowering drugs employed to slow the progression of glaucoma. The prosta-
glandin analogue class has gained ﬁ  rst-line therapy status with prescribers in recent 
years, largely due to unrivaled IOP-lowering efﬁ  cacy and favorable ocular and 
systemic safety. Travoprost’s IOP-lowering efﬁ  cacy and safety have been reported 
previously by Netland et al (2001); Goldberg et al (2001); Fellman et al (2002); and 
others (Parrish et al 2003).
Despite the ever-improving efﬁ  cacy and safety of new IOP-lowering drugs and 
classes, initial monotherapy is inadequate to control IOP in a substantial proportion of 
glaucoma patients. In the Ocular Hypertension Treatment Study, 40% of patients in the 
treatment arm required more than one medication to achieve a 20% IOP reduction (Kass 
et al 2002). Retrospective data demonstrate that more than 50% of patients prescribed 
initial monotherapy will undergo a treatment change within 2 years (Kobelt-Nguyen et al 
1998). And recent pharmacy services data demonstrate that at best, 30%–40% of patients 
prescribed monotherapy with a given IOP-lowering agent will still be actively reﬁ  lling 
prescriptions for that agent a year after the initiation of therapy (either due to patient 
non-adherence or a physician-directed change in therapy) (Reardon et al 2004).Clinical Ophthalmology 2007:1(3) 318
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These investigations have taken place since the availability 
of prostaglandin analogues, demonstrating that even with this 
new class of agents, adjunctive therapy is often required for 
long-term IOP control. Topical beta blockers are commonly 
used as adjunctive therapy with prostaglandins in clinical 
practice. Orengo-Nania and colleagues reported the safety 
and efﬁ  cacy of concomitant therapy with travoprost 0.004% 
and timolol 0.5% in patients with inadequate IOP control on 
timolol 0.5% alone (Orengo-Nania et al 2001). When travo-
prost 0.004% was added concomitantly to timolol 0.5% in 
this population of patients, additional mean IOP reductions 
ranging from 5.7 to 7.2 mmHg were observed, with no unex-
pected side effects following concomitant administration of 
the two drugs.
Subsequently, a ﬁ  xed combination of travoprost and 
timolol has been developed. The efﬁ  cacy and safety of 
travoprost 0.004% and timolol 0.5% in ﬁ  xed combination 
have recently been reported from two prospective, random-
ized, controlled clinical trials (Hughes et al 2005; Schuman 
et al 2005). Given the similarity of study designs, a pooled 
analysis is appropriate to further characterize the efﬁ  cacy of 
the ﬁ  xed combination compared to concomitant administra-
tion of its components.
Methods
Data from two clinical trials were pooled for the current analy-
sis. Each of these trials has been reported separately (Hughes 
et al 2005; Schuman et al 2005). The protocol for each trial 
was approved by Institutional Review Boards for participat-
ing sites and the studies were conducted in accordance with 
the Declaration of Helsinki and relevant ICH guidelines. All 
participating patients gave written informed consent.
In the ﬁ  rst trial, patients with open-angle glaucoma or ocu-
lar hypertension were randomized to receive either travoprost 
0.004%/timolol 0.5% ﬁ  xed combination once daily in the 
morning or concomitant administration of travoprost 0.004% 
dosed once daily in the evening and timolol 0.5% dosed once 
daily in the morning (Hughes et al 2005). The same two treat-
ment groups were included in the second trial. In addition, a 
timolol 0.5% arm dosed twice daily was included in the second 
trial for internal validation (Schuman et al 2005). (Data from 
the timolol-only arm are not included in this pooled analysis 
since it was in only one of the two studies.) In both studies, the 
primary efﬁ  cacy parameter was mean IOP at the 8 AM, 10 AM, 
and 4 PM time points at Week 2, Week 6, and Month 3. For 
each patient, the eye with the higher IOP at baseline was 
selected for analysis. The primary statistical objective for 
each study was to demonstrate non-inferiority of the ﬁ  xed 
combination to concomitant therapy. Primary efﬁ  cacy was 
pre-speciﬁ  ed in the protocol and analysis plan to be based 
upon IOP assessments collected through the Month 3 visit. 
In addition, patients remained on assigned masked treatment 
for an additional three months primarily for safety follow-up 
(providing up to 6 months total on masked therapy), although 
the ﬁ  rst 3 months remained the basis for primary efﬁ  cacy. The 
pooled analysis followed the same a priori statistical design 
set forth in the protocols for the individual studies.
Hypothesis tests were performed using repeated measures 
analysis of variance. Since primary efﬁ  cacy was a test of non-
inferiority, the analysis was based on the per protocol data set 
and conﬁ  rmed with intent-to-treat. All patients who received 
study medications and completed at least one study visit were 
included in the intent-to-treat data set. Last-observation-
carried-forward was used to impute missing values in the 
intent-to-treat data set. Further to the criteria for inclusion in 
the intent-to-treat analysis, patients were excluded from the 
per protocol data set if they did not satisfy pre-randomization 
inclusion/exclusion criteria. Also, data points potentially 
affected by protocol violations (eg, dosing non-adherence) 
were excluded from the per protocol analysis. Analysis of 
both data sets was planned to demonstrate robustness of study 
ﬁ  ndings. For the test of non-inferiority, a two-sided 95% 
conﬁ  dence interval for the treatment group difference was 
constructed at each visit and time point based on the analysis 
of variance. In order to demonstrate non-inferiority, all of the 
upper conﬁ  dence limits must have been less than or equal to 
+1.5 mmHg. The 1.5 mmHg non-inferiority margin is widely 
used, reported, and accepted as an appropriate margin for 
comparison of IOP-lowering medications.
Safety evaluation included adverse event reports, ocular 
parameters (logMAR visual acuity; ocular signs consist-
ing of cornea, iris/anterior chamber, lens, aqueous ﬂ  are, 
and inﬂ  ammatory cells; ocular hyperemia; dilated fundus 
examination consisting of vitreous, retina/macula/choroid, 
optic nerve, and cup/disc ratio; visual ﬁ  elds; iris and eyelash 
photography), and non-ocular parameters (pulse rate, systolic 
blood pressure, and diastolic blood pressure). Conjunctival 
hyperemia was assessed by study investigators on a scale 
ranging from 0 (none) to 3 (severe), in increments of 0.5, 
using a set of photographic standards of ocular hyperemia 
provided by Alcon Laboratories. Ocular photographs were 
taken using a Sony CD Mavica digital camera to assess iris 
color and eyelash changes from baseline. Other aspects of 
the two protocols, including inclusion and exclusion criteria, 
were similar and are described elsewhere (Hughes et al 2005; 
Schuman et al 2005).Clinical Ophthalmology 2007:1(3) 319
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Results
In total, 635 patients (322 travoprost 0.004%/timolol 0.5% 
and 313 concomitant therapy) are in the pooled analysis 
and were included in the evaluation of safety. Of these, 
622 patients (317 travoprost 0.004%/timolol 0.5% and 305 
concomitant therapy) were included in the intent-to-treat 
analysis and 599 patients (306 travoprost 0.004%/timolol 
0.5% and 293 concomitant therapy) were included in the 
per protocol analysis.
Mean IOP in the per protocol analysis at each visit and 
time point is given in Table 1. Baseline IOP ranged from 
23.1 to 25.4 mmHg in the ﬁ  xed combination group, and 
from 23.0 to 25.0 in the concomitant group. The difference 
of 0.4 mmHg in mean baseline IOP at 8 AM is not clinically 
relevant, although statistically signiﬁ  cant due to the pooled 
sample size. Mean on-therapy IOP ranged from 15.7 to 16.8 
mmHg in the ﬁ  xed combination group, and from 15.1 to 
16.4 mmHg in the concomitant group. Differences in mean 
IOP between groups (ﬁ  xed combination minus concomitant) 
ranged from 0.2 to 1.0 mmHg across visits and time points, 
with upper 95% conﬁ  dence limits for these differences rang-
ing from 0.7 to 1.5 mmHg, thereby satisfying the criterion for 
non-inferiority (less than or equal to 1.5 mmHg at all 9 time 
points). Mean IOP is shown graphically in Figure 1.
Mean IOP change from baseline at each visit and time 
point is given in Table 2. Mean IOP reductions were up to 
9.0 mmHg in the ﬁ  xed combination group, and up to 8.8 
mmHg in the concomitant group. Treatment-group differ-
ences ranged from –0.2 to +0.9 mmHg, with upper 95% 
limits ranging from 0.3 to 1.4 mmHg, again satisfying the 
criterion for non-inferiority.
The per protocol results were conﬁ  rmed in the intent-
to-treat analysis (data not shown). The upper 95% conﬁ  dence 
limits for treatment-group differences ranged from 0.6 to 1.4 
mmHg in the analysis of IOP, and from 0.2 to 1.3 mmHg in 
the analysis of IOP change from baseline. The concordance 
of the per protocol and intent-to-treat results demonstrate the 
robustness of ﬁ  ndings in the per protocol analysis with respect 
to missing data and truncated observations.
Adverse events in the overall population were predomi-
nately nonserious, generally mild to moderate in intensity, 
usually resolved with or without treatment, and generally 
did not interrupt continuing patient participation in the stud-
ies (see Table 3). Adverse events in the travoprost 0.004%
/timolol 0.5% group were similar in type and frequency to 
those seen in the group exposed to concomitant therapy of 
the individual components. Ocular hyperemia was the most 
frequent adverse event in those patients with exposure to tra-
voprost 0.004%/timolol 0.5% and in those with concomitant 
therapy of the individual components (13.7% and 20.8%, 
respectively, p = 0.02). In addition to the review of adverse 
events, no safety concerns were identiﬁ  ed based upon an 
analysis of ocular and nonocular parameters. Overall, travo-
prost 0.004%/timolol 0.5% ophthalmic solution administered 
once daily is safe and well tolerated with a similar safety 
proﬁ  le observed when compared with concomitant therapy 
with the individual components.
Discussion
This pooled analysis of two prospective, randomized, con-
trolled clinical trials demonstrates that the ﬁ  xed combination 
of travoprost and timolol offers comparable IOP reduction 
and a similar safety proﬁ  le to concomitant therapy with 
travoprost and timolol. Both mean IOP reduction and mean 
IOP were statistically similar between the two groups, 
with upper 95% conﬁ  dence limits for the between-group 
Table 1 Mean IOP comparison for test on non-inferiority
  Baseline  Week 2  Week 6  Month 3
  8 AM  10 AM  4 PM  8 AM  10 AM  4 PM  8 AM  10 AM  4 PM  8 AM  10 AM  4 PM
Trav 0.004%/Tim 0.5%
  Mean  25.4 24.0 23.1 16.8 16.2 15.7 16.4 16.2 15.9 16.8 16.3  16.0
  N  306 306 306 303 299 300 289 291 286 286 288  286
TRAV+Tim 0.5%
  Mean  25.0 23.9 23.0 16.4 15.5 15.1 16.2 15.2 15.1 16.4 15.5  15.2
  N  293 293 293 285 282 284 283 281 280 276 273  274
Difference  0.4 0.1 0.1 0.3 0.7 0.6 0.2 1.0 0.8 0.5 0.8  0.8
p-value  0.0438 0.7437 0.7670 0.1490 0.0049 0.0125 0.3874 0.0001 0.0008 0.0651 0.0012  0.0008
Upper  95%  CI  0.8 0.5 0.5 0.8 1.2 1.1 0.7 1.5 1.3 0.9 1.3  1.3
Lower  95%  CI  0.0  –0.3 –0.3 –0.1 0.2  0.1  –0.3 0.5  0.3  –0.0 0.3  0.3
Notes: Estimates based on least squares means and conﬁ  dence intervals from repeated measures analysis of variance. Baseline estimates obtained from separate model.
Abbreviations: Trav 0.004%/Tim 0.5%, travoprost 0.004%/timolol 0.5% ophthalmic solution; TRAV +Tim 0.5%, TRAVATAN® + timolol 0.5% ophthalmic solution.Clinical Ophthalmology 2007:1(3) 320
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Table 2 Mean IOP change from baseline comparison for test of non-inferiority
  Baseline  Week 2  Week 6  Month 3
  8 AM  10 AM  4 PM  8 AM  10 AM  4 PM  8 AM  10 AM  4 PM  8 AM  10 AM  4 PM
Trav 0.004%/Tim 0.5%
Mean  25.4 24.0 23.1 –8.6 –7.9 –7.4 –9.0 –7.9 –7.2 –8.6 –7.7  –7.1
N  306 306 306 303 299 300 289 291 286 286 288  286
TRAV+Tim 0.5%
Mean  25.0 23.9 23.0 –8.6 –8.5 –7.9 –8.8 –8.8 –7.9 –8.6 –8.4  –7.9
N  293 293 293 285 282 284 283 281 280 276 273  274
Difference  0.4 0.1 0.1 –0.0  0.6 0.5 –0.2  0.9 0.8 0.0 0.7  0.8
p-value  0.0438 0.7437 0.7670 0.8733 0.0235 0.0550 0.4611 0.0007 0.0042 0.9686 0.0071  0.0047
Upper  95%  CI  0.8 0.5 0.5 0.5 1.1 1.0 0.3 1.4 1.3 0.5 1.2  1.3
Lower  95%  CI  0.0  –0.3 –0.3 –0.6 0.1  –0.0 –0.7 0.4  0.2  –0.5 0.2  0.2
Notes: Estimates based on least squares means and conﬁ  dence intervals from repeated measures analysis of variance. Baseline estimates obtained from separate model.
Abbreviations: Trav 0.004%/Tim 0.5%, travoprost 0.004%/timolol 0.5% ophthalmic solution; TRAV + Tim 0.5%, TRAVATAN® + timolol 0.5% ophthalmic solution.
Figure 1 Comparison of mean IOP for travoprost 0.004%/timolol 0.5% ﬁ  xed 
combinaiton and concomitant travoprost 0.004% and timolol 0.5%.
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differences falling at or below 1.5 mmHg at all visits and 
time points.
Prostaglandin analogues and beta blockers are the 
most widely used IOP-lowering medications in the United 
States today (Fechtner and Realini 2004). This pattern of 
clinical drug usage is important in the context of the his-
tory of ﬁ  xed combinations of IOP-lowering drugs in the 
US. Several combinations of a miotic (pilocarpine) with 
an adrenergic agonist (epinephrine) were already in use at 
the time of the 1962 Harrison-Kefauver amendments to the 
Food, Drug, and Cosmetic Act and were “grandfathered”. 
These combinations were in ordinary clinical practice at 
a time when beta blockers, topical carbonic anhydrase 
inhibitors (CAI), and prostaglandin analogues did not 
exist for glaucoma management. Only two ﬁ  xed combi-
nations actually have achieved FDA regulatory approval, 
and both contained drugs which were widely used for 
concomitant dosing at the time that they were approved 
– i) a beta blocker (betaxolol) and a miotic (pilocarpine), 
which was not marketed and ii) a beta blocker (timolol) 
and a CAI (dorzolamide), which is still in use (Strohmaier 
et al 1998).
Data suggest that prostaglandin analogues may offer 
slightly more IOP reduction when dosed in the evening 
compared to the morning (Alm and Stjernschantz 1995) but 
beta blockers offer better aqueous suppression when dosed 
in the morning rather than the evening (Topper and Brubaker 
1985). Thus, the concomitantly treated arm in this pooled 
analysis exhibited a measurable, statistically signiﬁ  cant (only 
at 10 AM and 4 PM) but clinically irrelevant IOP beneﬁ  t by 
administering each component at its optimal time of day. 
The IOP-lowering efﬁ  cacy between travoprost/timolol ﬁ  xed 
combination and the concomitantly treated arm is similar at Clinical Ophthalmology 2007:1(3) 321
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beneﬁ  ts of ﬁ  xed combination therapy. Beneﬁ  ts of the ﬁ  xed 
combination for patients include fewer bottles and fewer 
drops per day, which may reduce confusion and enhance 
adherence. For patients with prescription drug beneﬁ  ts, the 
ﬁ  xed combination permits the purchase of two drugs with 
one co-payment. Safety may also be enhanced, as ﬁ  xed 
combination therapy reduces long-term exposure to preser-
vatives, which may over time lead to chronic conjunctival 
inﬂ  ammation (Baun et al 1995; Broadway et al 1994a) and 
reduced surgical success (Broadway et al 1994b; Lavin 
et al 1990) if trabeculectomy is ultimately required. There 
may also be efﬁ  cacy advantages, not only from improved 
affordability and improved adherence, but also by reducing 
the washout effect that arises when patients on multiple 
topical IOP-lowering medications instill successive medica-
tions too closely together, washing out medications before 
full therapeutic beneﬁ  ts are achieved (Serle JB, ARVO 
Abstract 971, 2004).
Importantly, the safety proﬁ  le of the travoprost/timolol 
ﬁ  xed combination was similar to the safety proﬁ  le seen with 
concomitant use. The side effects of the ﬁ  xed combination 
were the side effects expected from the two constituent 
drugs except that the reported hyperemia was signiﬁ  cantly 
(p = 0.02) less with the ﬁ  xed combination (13.7%) compared 
with the concomitant dosing (20.8%).
In summary, the ﬁ  xed combination of travoprost 0.004%/
timolol 0.5% dosed once daily in the morning provides statis-
tically equivalent IOP reduction to concomitant administra-
tion of travoprost 0.004% dosed once daily in the evening 
and timolol 0.5% dosed once daily in the morning. Mean 
IOP reductions on the travoprost/timolol ﬁ  xed combination 
were as much as 9.0 mmHg. Therapy with ﬁ  xed combina-
tions may offer many potential beneﬁ  ts to patients, including 
convenience, safety, cost, and efﬁ  cacy.
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